In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small ...
A treatment shown in initial studies to dramatically reduce death could become a "game-changer" in the treatment of liver disease ...
We appreciate FDA’s support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long-term adverse outcomes of these desperately ill children.
It has been suggested previously that fructose promotes the growth of some tumors directly—by serving as a fuel. Now, new ...
Many people assume most individuals addicted to opioids are young. But there’s also a significant population of 65+ addicted ...
They are also under pressure to collaborate, which is how Washington found herself in February at a gathering in New York City that was something like speed dating for scientists trying to cure ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...
That’s how I ended up in a phlebotomist’s chair at Quest Diagnostics at 7 a.m. on a recent Saturday, looking hard in the ...
Discover a study that examined the efficacy and safety of pemafibrate in 360 patients with MASLD and hypertriglyceridaemia.
Denifanstat treatment significantly improves liver disease activity among individuals with metabolic dysfunction-associated steatohepatitis.
Tune Therapeutics, an epigenome-editing company based in Durham and Seattle, will be the first to initiate a human clinical trial for an epigenetic therapy for a common infectious disease.